Hydroxychloroquine (HCQ) - Autophagy and TLR9 Inhibitor. CAS# 747-36-4 Catalog No.:M60302-10S Go6983 was dosed by IV

Go6983 was dosed by IV injection to mice bearing B16BL6 tumors at 22 μg per mouse

Tasquinimod

Clin Cancer Res

Pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma

and SMARCA2 (at 10 µM)

Hydroxychloroquine (HCQ) - Autophagy and TLR9 Inhibitor. CAS# 747-36-4 Catalog No.:M60302-10S Go6983 was dosed by IVHydroxychloroquine (HCQ), CAS No. 747 36 4, is a potent autophagy inhibitor and TLR9 inhibitor. It prevents lysosomal acidification, thereby interfering with a key step in the autophagic process. In cancer cells, HCQ treatment has been shown to cause increased apoptosis, tumor regression, and delay in tumor recurrence. HCQ was an effective growth inhibitor of human RCC cell lines, inhibiting growth, promoting apoptosis, and effecting cellular